SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132: 2557-2576.
  • 2
    Bajetta E, Procopio G, Colombo A, et al. Sorafenib in hepatocellular carcinoma. Clin Med Ther. 2009; 1: 277-287.
  • 3
    Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. 2005; 23: 8093-8108.
  • 4
    Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008; 112: 250-259.
  • 5
    Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7: 3129-3140.
  • 6
    Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24: 4293-4300.
  • 7
    Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
  • 8
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
  • 9
    Sorafenib [package insert]. Emeryville, CA; Bayer Healthcare Pharmaceuticals, Inc; 2009. http://berlex.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Accessed April 16, 2012.
  • 10
    Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009; 27: 3027-3035.
  • 11
    Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009; 10: 794-800.
  • 12
    Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010; 15: 285-292.
  • 13
    Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol. 2011; 29(suppl 15): 4000.
  • 14
    Dai Y, Hartandi K, Ji Z, et al. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 2007; 50: 1584-1597.
  • 15
    Albert DH, Tapang P, Magoc TJ, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006; 5: 995-1006.
  • 16
    Guo J, Marcotte PA, McCall JO, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006; 5: 1007-1013.
  • 17
    Wong CI, Koh TS, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol. 2009; 27: 4718-4726.
  • 18
    Jasinghe VJ, Xie Z, Zhou J, et al. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol. 2008; 49: 985-997.
  • 19
    Bruix J, Sherman M, Llovet JM, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421-430.
  • 20
    Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 21
    National Cancer Institute. Common Terminology Criteria for Adverse Events. Version 3.0 (CTCAE). Bethesda, MD: National Cancer Institute; 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed April 16, 2012.
  • 22
    Badvie S. Hepatocellular carcinoma. Postgrad Med J. 2000; 76: 4-11.
  • 23
    Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009; 27: 446-452.
  • 24
    Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006; 12: 1175-1181.
  • 25
    Bewick V, Cheek L, Ball J. Statistics review 12: survival analysis. Crit Care. 2004; 8: 389-394.
  • 26
    Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol. 2010; 22: 492-497.
  • 27
    Durazo FA, Blatt LM, Corey WG, et al. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23: 1541-1548.
  • 28
    Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004; 37: 529-540.
  • 29
    Takahashi H, Kurishima K, Ishikawa H, et al. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. Anticancer Res. 2010; 30: 3833-3837.
  • 30
    Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009; 32: 471-482.
  • 31
    Chun JM, Kwon HJ, Sohn J, et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol. 2011; 103: 148-151.
  • 32
    Luo Y, Jiang F, Cole TB, et al. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. Cancer Chemother Pharmacol. 2012; 69: 911-921.
  • 33
    Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006; 11: 790-800.
  • 34
    Park JW, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011; 17: 1973-1983.
  • 35
    Toh HC, Chen PJ, Knox J, et al. Phase 2 Trial of Linifanib in Patients With Advanced Hepatocellular Carcinoma: Analysis by Chinese and Non-Chinese Ethnicity. In: The ILCA Book of Abstracts of the Fifth International Liver Cancer Association; September 2-4, 2011; Hong Kong. Abstract P-211.
  • 36
    Yau T, Chan P, Ng K, et al. Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients. J Clin Oncol. 2008; 26(suppl 15): 15513.
  • 37
    Abou-Alfa GK, Amadori D, Santoro A, et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? [abstract]. J Clin Oncol. 2008; 26(suppl 15): 4518.
  • 38
    Gupta N, Chiu Y, Toh H, et al. Preliminary pharmacokinetics (PK) and safety comparison of Child-Pugh A (CPA) vs. Child-Pugh B (CPB) patients (pts) enrolled in a phase 2 study in hepatocellular carcinoma (HCC) [abstract]. Ann Oncol. 2010; 21(suppl 8): viii225-viii249. Abstract 752P.
  • 39
    Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304: 2154-2160.
  • 40
    Finn RS, Poon RTP, Yau T, et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol. 2011; 29(suppl 15): 4074.
  • 41
    Yau T, Chen PJ, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res. 2011; 17: 6914-6923.
  • 42
    Nagaoka S, Yoshida T, Akiyoshi J, et al. Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int. 2007; 27: 1091-1097.
  • 43
    Kang SH, Kim do Y, Jeon SM, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol. 2012; 24: 849-856.
  • 44
    Kinoshita A, Onoda H, Takano K, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma [published online ahead of print March 30, 2012]. Med Oncol.
  • 45
    Lopez JB, Balasegaram M, Thambyrajah V. Serum CA 125 as a marker of hepatocellular carcinoma. Int J Biol Markers. 1996; 11: 178-182.
  • 46
    Lopez JB. Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev. 2005; 26: 65-79.
  • 47
    National Institutes of Health. Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC). Protocol (NCT01009593). http://clinicaltrials.gov/. Accessed April 16, 2012.